Jump to any asset
As of September 9, 2026, Novo Nordisk A/S Sponsored (NVO) trades at $44.56. CleaRank Financial AI rates it Hold with a fair value of $45.25, 1.5% above the current price. Wall Street's consensus target is $45.25 across 14 analysts. RSI at 42 is in neutral territory, and the price is below its 50-day average of $47.75.
Novo Nordisk A/S Sponsored (NVO)
Novo Nordisk A/S Sponsored NYSE
$44.56
-0.6000 (-1.33%)
At close: Sep 9, 4:00 PM EDT
AI Analyst Consensus
55 / 100
Novo Nordisk A/S (NVO) is currently trading at $44.56, below its 50-day and 200-day moving averages ($47.75 and $46.31), indicating a bearish short-term trend. The company faces projected revenue declines of 3.00% in the current quarter and 7.00% in the next quarter, though a return to 2.00% growth is anticipated for next year. This near-term outlook, coupled with a 'Hold' consensus from 14 Wall Street analysts, suggests a period of consolidation rather than significant upside. The stock's valuation, with a P/E ratio of 11.14, appears attractive compared to broader market averages, but this must be viewed in the context of its projected revenue contraction. Key risks include the competition within the drug manufacturing sector and the potential for slower-than-expected revenue recovery. However, the company's established market position and ongoing research and development efforts provide a foundation for future growth.
NVO Price Analysis
Market Metrics
Open
$45.00
Day Range
$44.52 to $45.40
Prev Close
$45.16
Volume
8.79M
52-Week Range
$35.12 to $64.16
Market Cap
$196.91B
Peer Benchmarking
Valuation vs Sector (Healthcare)
Performance vs XLV
Sector Position Analysis
Trading at a notable discount to sector peers (-56%), which may indicate undervaluation or specific company headwinds.
NVO Financial Performance
Revenue vs. Earnings
Annual
Quarterly
NVO Analysis
Company's Health
4/5
12-Month Analyst Target
+1.55% Upside
Median of 14 analysts (12-month)
$45.25
AI Technical Analysis
Novo Nordisk A/S (NVO) is currently trading below its 50-day and 200-day moving averages ($47.75 and $46.31), signaling a bearish trend over the past quarter. The Relative Strength Index (RSI) is at 41.82, indicating neutral momentum, neither overbought nor oversold. The Moving Average Convergence Divergence (MACD) is also negative at -0.46, further suggesting downward pressure. Key support levels are not explicitly provided, but the current price of $44.56 is below its 20-day exponential moving average of $46.34. Volume has been slightly below average, with the latest volume at 8.79 million compared to an average of 9.51 million, suggesting a lack of strong conviction from traders. The chart structure implies potential for further downside if key moving averages continue to act as resistance.
ProTips
- Novo Nordisk's current price is below its 50-day and 200-day moving averages ($47.75 and $46.31), suggesting a bearish technical trend; consider waiting for a confirmed trend reversal before initiating new positions.
- With a median analyst price target of $45.25 and current price at $44.56, the analyst upside is minimal (1.5%), indicating that Wall Street sees limited immediate room for appreciation.
- As a major player in the drug manufacturing sector, Novo Nordisk is subject to intense competition and regulatory scrutiny; diversification within the healthcare sector may be prudent for risk management.
Key Catalysts
Bearish
Projected Revenue Declines
Novo Nordisk is forecasted to experience revenue declines of 3.00% in the current quarter and 7.00% in the next quarter year-over-year, potentially pressuring the stock price.
Source: Wall Street EstimatesBearish
Bearish Technical Indicators
The stock is trading below its 50-day and 200-day moving averages ($47.75 and $46.31), with a neutral RSI and negative MACD, indicating bearish momentum and potential for further price weakness.
Source: Technical AnalysisNeutral
Return to Growth Expected
Despite near-term declines, revenue growth is projected to return to 2.00% in the next year, suggesting a temporary slowdown rather than a fundamental business issue.
Source: Wall Street EstimatesBullish
Attractive Valuation
Novo Nordisk's P/E ratio of 11.14 is significantly lower than the sector average of 25.5, offering a potentially attractive entry point for long-term investors if growth re-accelerates.
Source: Fundamental AnalysisMarket Outlook
The base case scenario for Novo Nordisk A/S (NVO) over the next 6-12 months anticipates a stabilization and return to modest growth after a projected period of revenue contraction. With a median analyst price target of $45.25, the stock is currently trading near this level, suggesting limited immediate upside but also a degree of valuation support. The company's ability to execute on its product pipeline and manage near-term revenue challenges will be key to achieving sustainable growth. Potential catalysts for upside include stronger-than-expected revenue recovery or positive clinical trial results, which could shift analyst sentiment and drive the stock towards its higher price targets. Conversely, persistent revenue declines, increased competition, or regulatory hurdles could lead to a downside scenario, potentially pushing the stock towards its lower support levels. Investors should monitor upcoming earnings reports for signs of revenue stabilization and future growth prospects.
Key Statistics
| Market Cap | 196.91B |
|---|---|
| P/E Ratio | 11.14 |
| EPS (TTM) | 4.07 |
| Dividend Yield | 4.16% |
| 52 Week High | 64.16 |
| 52 Week Low | 35.12 |
Novo Nordisk A/S (NVO) presents a P/E ratio of 11.14, which is significantly lower than the sector average of 25.5, suggesting a potentially undervalued stock on a trailing earnings basis. However, this valuation must be considered alongside the projected revenue declines for the current and next quarters, which are -3.00% and -7.00% year-over-year, respectively. The company is expected to return to modest growth of 2.00% next year. The balance sheet strength is not detailed, but the company's ability to navigate near-term revenue headwinds will be critical. The current valuation appears to price in some of the near-term challenges, but sustained growth recovery will be necessary to drive significant upside.
Earnings & Growth Analysis
Novo Nordisk A/S (NVO) is facing a period of projected revenue contraction, with the current quarter estimated at $72.8 billion, a 3.00% decrease year-over-year. The next quarter's revenue is forecast at $73.9 billion, down 7.00% year-over-year. While the current year's revenue is expected to decline by 3.00% to $299.4 billion, analysts anticipate a return to 2.00% growth in the upcoming year, reaching $303.9 billion. This pattern suggests a temporary slowdown rather than a fundamental decline in the business.
Key Risks
Novo Nordisk A/S (NVO) faces near-term revenue headwinds, with projected year-over-year declines in the current and next quarters. The stock's current price is trading below key moving averages, indicating bearish technical momentum. Also, the median Wall Street price target of $45.25 offers minimal upside from the current price of $44.56, suggesting limited immediate catalysts for significant price appreciation.
Technical Indicators
| RSI (14) | 41.82 |
|---|---|
| MACD | -0.46 |
| SMA 50 | 47.75 |
| SMA 200 | 46.31 |
RSI
Neutral
SMA Cross
Bullish
Price vs SMA
Bearish
MACD
Bearish
Golden Cross in effect with the 50-day SMA ($47.75) above the 200-day SMA ($46.31), price is trading below the 50-day SMA.
Market Correlations
How this stock moves relative to other assets
Based on 1 year of daily price data. Correlations may vary over different time periods.
S&P 500 (SPY)
+0.29
Weak correlation
Nasdaq 100 (QQQ)
+0.24
Weak correlation
Bitcoin (BTC)
+0.41
Moderate correlation
Gold (XAU)
+0.04
Weak correlation
Check Custom Correlation
Calculating correlation...
NVO Trade Plans
Specific entry, exit, and risk management levels
Select Your Trade Bias
Risk Tolerance
Conservative
2%
Aggressive
Portfolio Value
$
Position Size: Enter portfolio size →
Entry Strategies (click to switch)
CONSERVATIVE
$44.11
Slight discount to current
Wait for small dip
AGGRESSIVE
$44.56
At current price
Enter now if confident
Risk Management
STOP LOSS
$42.35
MAX LOSS
-4.0%
Volatility-Adjusted Stop Loss
Calculated based on RSI (41.8) and current market volatility
Profit Targets (Based on Conservative Entry)
TARGET 1
$45.44
+3% (Conservative)
+2.0% (Aggressive)
TARGET 2
$46.32
+5% (Conservative)
+4.0% (Aggressive)
TARGET 3
$47.64
+8% (Conservative)
+6.9% (Aggressive)
Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3
Calculate Your Trade
Disclaimer
This AI-generated trade plan for NVO is for educational and informational purposes only and does not constitute financial advice. The analysis is based on historical data patterns and technical indicators which may not predict future results. Stock trading involves risk of loss. Verify all data independently and consult a qualified financial advisor. Generated on September 9, 2026.Growth of $10,000
A $10,000 investment in NVO in September 2016 would be worth about $20,509 today, compared with about $35,913 for the same investment in the S&P 500 benchmark.
Compare with Another Ticker
Monte Carlo Projection (10yr)
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in NVO today could grow to about $20,279 by 2036 in the base case, with a bull case near $77,746 and a bear case around $5,290. Projections are statistical simulations, not guarantees.
NVO Stock Price Prediction: 2030
CleaRank's simulation projects a price near $59.12 for NVO by 2030 in the base case, from $44.56 today (1.3x over 4 years). The downside path ends near $25.27. These are outcomes of a Monte Carlo simulation run on NVO's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | Downside (10th pct) | Base case | Upside (90th pct) |
|---|---|---|---|
| 2027 | $31.27 | $47.82 | $73.15 |
| 2028 | $28.14 | $51.33 | $93.62 |
| 2029 | $26.39 | $55.09 | $115 |
| 2030 | $25.27 | $59.12 | $138 |
| 2031 | $24.53 | $63.46 | $164 |
| 2032 | $24.05 | $68.10 | $193 |
| 2033 | $23.75 | $73.09 | $225 |
| 2034 | $23.58 | $78.45 | $261 |
| 2035 | $23.53 | $84.20 | $301 |
| 2036 | $23.57 | $90.36 | $346 |
Method: 10,000 simulated price paths using NVO's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice.
People Also Watch
Frequently Asked Questions
What is Novo Nordisk's stock price forecast for 2030?
Based on Monte Carlo simulations, Novo Nordisk's stock price is projected to be $59.12 by 2030 under base case assumptions, with a downside projection of $25.27 and an upside projection of $138.32. These figures represent simulation outcomes, not guaranteed price targets.
Is Novo Nordisk A/S stock a buy right now?
Novo Nordisk A/S (NVO) is currently rated a 'Hold' by Wall Street analysts, with a median price target of $45.25, offering only 1.5% upside from its current price of $44.56. The stock is trading below its key moving averages, indicating bearish technical momentum.
What are the key risks for Novo Nordisk A/S?
Key risks for Novo Nordisk include projected near-term revenue declines of up to 7.00% year-over-year, bearish technical indicators such as trading below its 50-day and 200-day moving averages ($47.75 and $46.31), and a limited upside potential to its median analyst price target.
How does Novo Nordisk's valuation compare to its sector?
Novo Nordisk's P/E ratio of 11.14 is significantly lower than the Healthcare sector average of 25.5, suggesting it may be undervalued on a trailing earnings basis. However, this is tempered by projected near-term revenue declines.
What is the long-term outlook for Novo Nordisk A/S?
The long-term outlook for Novo Nordisk A/S appears stable, with revenue growth expected to return to 2.00% in the next year after a projected dip. The company's established market position and ongoing R&D provide a foundation for sustained performance, though near-term revenue challenges need to be monitored.
What is Novo Nordisk's revenue growth projection?
Novo Nordisk is projected to experience revenue declines of 3.00% in the current quarter and 7.00% in the next quarter year-over-year. However, revenue growth is expected to rebound to 2.00% in the next year.
What is the consensus rating for Novo Nordisk stock?
The consensus rating for Novo Nordisk A/S (NVO) stock is 'Hold', with 14 Wall Street analysts covering the stock. There are no 'Strong Buy' or 'Sell' ratings, with the majority holding a 'Hold' position.